✦ LIBER ✦

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer

✍ Scribed by Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall K. Gibb; Lynne Lippmann; Robert L. Coleman; David G. Mutch

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II evaluation of a 3-day infusion

✍ Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall Gibb; David G. Mutc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Topotecan in heavily pretreated patients

✍ B. PIURA; A. RABINOVICH 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Beyond tertiary cytoreduction in patient

✍ K.K. Shih; D.S. Chi; R.R. Barakat; M.M. Leitao Jr. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Phase II study of bevacizumab and pemetr

✍ Hagemann, Andrea R.; Novetsky, Akiva P.; Zighelboim, Israel; Gao, Feng; Massad, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 264 KB

Phase 1–2 study of docetaxel plus aflibe

✍ Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 208 KB

Topotecan in patients with BRCA-associat

✍ David M. Hyman; Qin Zhou; Angela G. Arnold; Rachel N. Grisham; Alexia Iasonos; N 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 299 KB